CTX001
AssetAlso Casgevy
- Stage
- Phase 1
- Modality
- Gene therapy
- Target
- Not known
- 4
- Indications
- 78
- Trials
- 2
- Developers
Indications
4Anemia
Phase 1, Recruiting, NCT07577817, clinicaltrials.gov, 7 Oct 2026
Chronic kidney disease
Phase 1, Recruiting, NCT07577817, clinicaltrials.gov, 7 Oct 2026
Geographic atrophy secondary to age-related macular degeneration
Phase 1, Recruiting, NCT07392255, clinicaltrials.gov, 10 Oct 2026
1 more
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials78
- Evidence for its targets1
- Competitors3
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.